Q1 Earnings Estimate for CLDX Issued By HC Wainwright

Celldex Therapeutics, Inc. (NASDAQ:CLDX) – Equities research analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for shares of Celldex Therapeutics in a note issued to investors on Friday, February 28th. HC Wainwright analyst J. Pantginis expects that the biopharmaceutical company will earn ($0.73) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $80.00 target price on the stock. The consensus estimate for Celldex Therapeutics’ current full-year earnings is ($2.48) per share.

A number of other equities research analysts also recently issued reports on the stock. The Goldman Sachs Group decreased their price target on Celldex Therapeutics from $42.00 to $36.00 and set a “neutral” rating on the stock in a research note on Monday. UBS Group initiated coverage on Celldex Therapeutics in a research report on Thursday, February 13th. They set a “buy” rating and a $44.00 target price on the stock. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $67.00 price target on shares of Celldex Therapeutics in a research report on Wednesday, January 29th. Two analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Celldex Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $55.38.

Celldex Therapeutics Trading Down 5.9 %

CLDX stock opened at $19.35 on Monday. The company’s 50-day moving average price is $23.75 and its 200 day moving average price is $28.80. Celldex Therapeutics has a 52 week low of $19.31 and a 52 week high of $53.18. The company has a market cap of $1.28 billion, a P/E ratio of -7.53 and a beta of 1.60.

Celldex Therapeutics (NASDAQ:CLDX) last issued its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.71) EPS for the quarter, topping the consensus estimate of ($0.73) by $0.02. The company had revenue of $1.18 million for the quarter, compared to analyst estimates of $1.25 million. Celldex Therapeutics had a negative net margin of 1,544.32% and a negative return on equity of 19.75%.

Institutional Trading of Celldex Therapeutics

A number of large investors have recently made changes to their positions in CLDX. Creative Planning purchased a new position in Celldex Therapeutics in the 3rd quarter valued at about $504,000. Emerald Mutual Fund Advisers Trust boosted its position in Celldex Therapeutics by 92.0% during the third quarter. Emerald Mutual Fund Advisers Trust now owns 243,795 shares of the biopharmaceutical company’s stock worth $8,287,000 after acquiring an additional 116,832 shares during the last quarter. Emerald Advisers LLC grew its stake in Celldex Therapeutics by 129.9% in the 3rd quarter. Emerald Advisers LLC now owns 456,202 shares of the biopharmaceutical company’s stock worth $15,506,000 after acquiring an additional 257,773 shares during the period. GSA Capital Partners LLP raised its holdings in Celldex Therapeutics by 191.2% in the 3rd quarter. GSA Capital Partners LLP now owns 16,114 shares of the biopharmaceutical company’s stock valued at $548,000 after acquiring an additional 10,581 shares during the last quarter. Finally, KBC Group NV lifted its stake in shares of Celldex Therapeutics by 31.2% during the 3rd quarter. KBC Group NV now owns 2,081 shares of the biopharmaceutical company’s stock worth $71,000 after purchasing an additional 495 shares during the period.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.